^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Rui Lisheng (romiplostim biosimilar)

    i
    Other names: QL0911
    Associations

    News

    Trials
    Company:
    Qilu Pharma
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    Associations

    News

    Trials
    28d
    Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=63, Completed, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Completed | Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: May 2023 --> Feb 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    Rui Lisheng (romiplostim biosimilar)
    5ms
    QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=235, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Rui Lisheng (romiplostim biosimilar)
    over1year
    Evaluating the Efficacy and Safety of QL0911 in Chemotherapy- Induced Thrombocytopenia (clinicaltrials.gov)
    P2/3, N=50, Completed, Qilu Pharmaceutical Co., Ltd.
    New P2/3 trial
    |
    Rui Lisheng (romiplostim biosimilar)